Headquartered in Brisbane, CA Fiscal year ends December NASDAQ: PCRX pacira.com
Pacira BioSciences is an innovation-driven biopharmaceutical company focused on non-opioid pain management therapies. The company markets two commercial-stage products: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for postsurgical pain management via infiltration and several nerve block indications in adults and children aged 6 and older; and ZILRETTA (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release intra-articular therapy for osteoarthritis-related knee pain. Pacira recently divested its iovera° cryoanalgesia device business to Zimmer Biomet to sharpen its biopharmaceutical focus. The company is advancing a clinical-stage pipeline anchored by PCRX-201 (enekinragene inzadenovec), a locally administered gene therapy in Phase 2 development for knee osteoarthritis, built on its proprietary high-capacity adenovirus (HCAd) vector platform acquired through the purchase of GQ Bio. This platform enables efficient gene delivery at lower doses with potential for redosing, and the company has identified additional cytokine-based gene therapy candidates for future development. Pacira generates revenue primarily through direct product sales and royalty income, with bupivacaine liposome injectable suspension also licensed to third-party partners. Updated
Friday's top analyst upgrades and downgrades included AT&T, Exxon Mobil, Hasbro, Juniper Networks, Moderna, Palo Alto Networks, Snap, Teva Pharmaceutical, Under Armour and Zscaler.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Monday, including Gap, Palo Alto Networks, Schlumberger and Spotify.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Thursday, including Cisco, Lyft, Uber, VMware and more.
Friday's top analyst upgrades, downgrades and initiations Apple, Centene, Comcast, Electronic Arts, Facebook, Intel, PG&E, Procter & Gamble, SLM, Take-Two Interactive Software and Travelers.
Here are 20 biotechnology and pharmaceutical stocks that have been given big analyst upside targets for 2020.
Here are 11 biotech and pharma stocks that have been given big analyst upside targets for 2020.
The top analyst upgrades, downgrades and other research calls from Monday include Applied Materials, Barrick Gold, Comcast, GoDaddy, Intel, PG&E, Qualcomm and Sirius XM.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) has found itself in the middle of a great opportunity but not being able to make the last mile of the race. Unfortunately, pain management in a…
Jon C. Ogg Here is a 24/7 Wall St. calendar with a few of the biggest biotech and pharmaceutical companies expecting clinical trial and FDA updates in April.
The top analyst upgrades, downgrades and other research calls from Wednesday include Allergan, Autodesk, Home Depot, Marvell, Qualcomm, UnitedHealth and Walmart.
The top analyst upgrades, downgrades and other research calls from Thursday include Biogen, Cabot Oil & Gas, CenturyLink, NetApp, Square, T-Mobile and Wix.com.
The top analyst upgrades, downgrades and other research calls from Thursday include Barrick Gold, Buffalo Wild Wings, Caterpillar, Coca-Cola, GrubHub, Nabors Industries and Wynn Resorts.
Stocks were indicated to open marginally lower on Monday ahead of the Great American Eclipse, but investors need to keep in mind that the markets are still very close to all-time highs.…
The top analyst upgrades, downgrades and initiations seen on Thursday include Adobe, ClubCorp, Oracle, Silver Wheaton, Weatherford International and Yahoo.
In this week's top stock picks from Jefferies, three very prominent biotechnology stocks are featured, including one that is a large cap leader.
Pacira BioSciences is an innovation-driven biopharmaceutical company focused on non-opioid pain management therapies.
The Wall Street consensus 12-month price target for PCRX is $30.00.
